News

Technology News

Civitas Publishes Positive Parkinsons Treatment Results

Monday, April 22, 2013 5:01:00 AM PDT | VentureDeal
   Chelsea, Massachusetts  --  Pharmaceutical company Civitas Therapeutics has announced positive phase 2 clinical results for its treatment for Parkinson's disease.

CVT-301, an inhaled formulation of levodopa, is in development as a treatment for intermittent debilitating motor fluctuations that affect a large portion of patients.

If successful, the medication promises to provide more consistent and effective L-dopa absorption and plasma concentrations in patients.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1